Gonadotropin chorionic, lyophilisate 1000 me 5 pcs

Gonadotropin chorionic is a gonadotropic hormone. It is produced by the human placenta and excreted in the urine, from where it can be extracted and purified. It stimulates the production of progesterone by the corpus luteum and supports the development of the placenta. It has a gonadotropic effect, mainly luteinizing.

Pharmacokinetics

The drug is well absorbed after I/m injection. T1/2 is 8 h.

Chorionic gonadotropin is believed to be modified in the body prior to excretion with the urine because its T1/2 as measured by immunological method is significantly greater than that determined by biological activity.

Indications

For women: ovarian dysfunction (anovulatory), amenorrhea; induction of ovulation in case of infertility caused by anovulation or impaired follicle maturation; maintaining the corpus luteum phase; preparation of follicles for puncture in programs of controlled ovarian hyperstimulation (for assisted reproductive technologies).

For boys and men: delayed puberty due to insufficiency of the gonadotropic function of the pituitary gland; cryptorchidism not caused by anatomical obstruction; insufficiency of spermatogenesis, oligoasthenospermia, azoospermia; when conducting a differential diagnostic test for anorchism and cryptorchidism in boys; when performing a functional Leydig test to assess testicular function in hypogonadotropic hypogonadism before starting long-term stimulating treatment.

Pharmacological effect

Pharmacotherapeutic group: Luteinizing agent

Pharmacological action

Gonadotropic hormone. Produced by the human placenta and excreted in urine, from where it can be extracted and purified. Stimulates the production of progesterone by the corpus luteum and supports the development of the placenta. It has a gonadotropic effect, predominantly luteinizing.

In women, the drug causes ovulation and stimulates the synthesis of estrogen and progesterone. In men, it stimulates spermatogenesis and the production of sex steroids.

Pharmacokinetics

After intramuscular administration it is well absorbed. T1/2 is 8 hours.

It is believed that before being excreted in the urine, human chorionic gonadotropin is modified in the body, because its T1/2, measured by the immunological method, significantly exceeds this indicator, determined by biological activity.

Special instructions

Long-term use is not recommended due to the possible formation of antibodies that reduce the effectiveness of treatment.

If ovarian hyperstimulation syndrome develops, discontinue use.

Active ingredient

Chorionic gonadotropin

Composition

Active substance: human chorionic gonadotropin

Pregnancy

Contraindicated for use during pregnancy and breastfeeding.

Contraindications

Hormone-dependent malignant tumors of the genital organs and breast (ovarian cancer, uterine cancer, breast cancer in women); androgen-dependent tumors (prostate cancer, breast cancer, testicular tumor); the presence of cysts or an increase in the size of the ovaries, not associated with polycystic ovary syndrome; bleeding or spotting from the vagina of unknown etiology; history of ectopic pregnancy (3 months before the start of treatment); primary ovarian failure; abnormal development of the genital organs in women, incompatible with the normal course of pregnancy; uterine fibroids incompatible with pregnancy; menopause; conditions associated with undescended testicle into the scrotum (inguinal hernia, surgical operations in the groin area, ectopic testicle); organic lesions of the central nervous system (including tumors of the pituitary gland, hypothalamus); deep vein thrombophlebitis; hypothyroidism; adrenal insufficiency; hyperprolactinemia; pregnancy, breastfeeding period; children under 3 years of age.

With caution

IHD, chronic heart failure, epilepsy, migraine (including a history), chronic renal failure, arterial hypertension, in women with risk factors for thrombosis; in prepubertal boys.

Side Effects

From the endocrine system in women: possible development of ovarian hyperstimulation syndrome, accompanied by the development of ovarian cysts with the risk of their rupture, ascites, hydrothorax and the risk of thromboembolism.

From the endocrine system in boys and men: possible temporary reversible enlargement of the mammary glands, prostate gland, water and electrolyte retention, acne vulgaris;

In boys, behavioral changes similar to those observed during the first phase of puberty are possible, which disappear after the end of treatment.

Storage conditions

In a place protected from light, at a temperature not exceeding 20 °C

Shelf life

4 years

Manufacturer

Moscow Endocrine Plant, Russia